Jazz Pharmaceuticals Plc Given “Neutral” Rating at Zacks (JAZZ)
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)‘s stock had its “neutral” rating reiterated by Zacks in a research report issued to clients and investors on Friday, AR Network reports. They currently have a $167.00 price objective on the stock. Zacks‘ price target would indicate a potential upside of 4.99% from the stock’s previous close.
Zacks‘ analyst wrote, “We are initiating coverage on Jazz with a Neutral recommendation and a target price of $167.00. We are encouraged by the strong growth exhibited by key products Xyrem and Erwinaze. Both should continue performing well. We are also positive on Jazz’ efforts to boost sales through label expansions. The company also remains active on the deal making front and we are positive on recent deals like the upcoming Gentium acquisition and the acquisition of rights to ADX-N05. We believe the company will continue to pursue such deals to boost its product portfolio and pipeline. Meanwhile, the Xyrem patent litigation remains a matter of concern. “
Shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded down 4.14% during mid-day trading on Friday, hitting $152.49. 935,654 shares of the company’s stock traded hands. Jazz Pharmaceuticals Plc has a 52 week low of $50.76 and a 52 week high of $159.14. The stock’s 50-day moving average is $129.4 and its 200-day moving average is $98.08. The company has a market cap of $8.812 billion and a price-to-earnings ratio of 27.03.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.78 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.67 by $0.11. The company had revenue of $232.20 million for the quarter, compared to the consensus estimate of $227.38 million. During the same quarter last year, the company posted $1.29 earnings per share. Jazz Pharmaceuticals Plc’s revenue was up 32.3% compared to the same quarter last year. Analysts expect that Jazz Pharmaceuticals Plc will post $6.37 EPS for the current fiscal year.
JAZZ has been the subject of a number of other recent research reports. Analysts at UBS AG raised their price target on shares of Jazz Pharmaceuticals Plc from $130.00 to $164.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Separately, analysts at R. F. Lafferty downgraded shares of Jazz Pharmaceuticals Plc from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, January 14th. They now have a $140.00 price target on the stock. Finally, analysts at Brean Capital raised their price target on shares of Jazz Pharmaceuticals Plc to $171.00 in a research note to investors on Friday, December 20th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Jazz Pharmaceuticals Plc presently has an average rating of “Buy” and an average price target of $116.94.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.